CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Mar 14

PMID 35280988

Authors

Massimiliano Gambella

Simona Carlomagno

Anna Maria Raiola

Livia Giannoni

Chiara Ghiggi

Chiara Setti

Chiara Giordano

Silvia Luchetti

Alberto Serio

Alessandra Bo

Michela Falco

Mariella Della Chiesa

Emanuele Angelucci

Simona Sivori

Affiliations

Soon will be listed here.

Abstract

Surgical resection, chemotherapy and radiotherapy were, for many years, the only available cancer treatments. Recently, the use of immune checkpoint inhibitors and adoptive cell therapies has emerged as promising alternative. These cancer immunotherapies are aimed to support or harness the patient's immune system to recognize and destroy cancer cells. Preclinical and clinical studies, based on the use of T cells and more recently NK cells genetically modified with chimeric antigen receptors retargeting the adoptive cell therapy towards tumor cells, have already shown remarkable results. In this review, we outline the latest highlights and progress in immunotherapies for the treatment of Diffuse Large B-cell Lymphoma (DLBCL) patients, focusing on CD19-targeted immunotherapies. We also discuss current clinical trials and opportunities of using immunotherapies to treat DLBCL patients.

Citing Articles

CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

Khunti N, Kumar M, Datta M, Harelimana J, Harms M, Albers D Int J Mol Sci. 2025; 26(5).

PMID: 40076664 PMC: 11899823. DOI: 10.3390/ijms26052024.

Identification of a Novel Immune-Gene Signature with Prognostic Value in Patients with Head and Neck Cancer: A Pilot Study.

Batsaki P, Fortis S, Gritzapis A, Razou A, Sakellaridis A, Grouzi E Biochem Genet. 2025; .

PMID: 39779579 DOI: 10.1007/s10528-024-11017-8.

Contemplating the prognostic and therapeutic potential of CD19: a comprehensive analysis across diverse cancer types.

Yang X, Duan Y, Zhao Z Am J Transl Res. 2024; 16(11):6365-6383.

PMID: 39678610 PMC: 11645609. DOI: 10.62347/KJGS9928.

Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.

Slezak A, Chang K, Beckman T, Refvik K, Alpar A, Lauterbach A Blood Adv. 2024; 8(7):1747-1759.

PMID: 38324726 PMC: 10985806. DOI: 10.1182/bloodadvances.2023012529.

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.

Kim H, Han M, Kim M, Kim H, Im H, Kim N Oncol Lett. 2023; 25(6):236.

PMID: 37153038 PMC: 10161343. DOI: 10.3892/ol.2023.13822.

References

Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter S . Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia. 2013; 27(6):1263-74. PMC: 4249624. DOI: 10.1038/leu.2013.5. View

Tanaka J, Miller J . Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Rev. 2020; 44:100678. DOI: 10.1016/j.blre.2020.100678. View

Jurczak W, Zinzani P, Gaidano G, Goy A, Provencio M, Nagy Z . Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018; 29(5):1266-1272. PMC: 5961010. DOI: 10.1093/annonc/mdy056. View

Chung E, Psathas J, Yu D, Li Y, Weiss M, Thomas-Tikhonenko A . CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012; 122(6):2257-66. PMC: 3366393. DOI: 10.1172/JCI45851. View

Duell J, Maddocks K, Gonzalez-Barca E, Jurczak W, Liberati A, de Vos S . Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021; 106(9):2417-2426. PMC: 8409029. DOI: 10.3324/haematol.2020.275958. View

Awan F, Lapalombella R, Trotta R, Butchar J, Yu B, Benson Jr D . CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2009; 115(6):1204-13. PMC: 2826232. DOI: 10.1182/blood-2009-06-229039. View

Strati P, Ahmed S, Kebriaei P, Nastoupil L, Claussen C, Watson G . Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020; 4(13):3123-3127. PMC: 7362369. DOI: 10.1182/bloodadvances.2020002328. View

Xie G, Dong H, Liang Y, Ham J, Rizwan R, Chen J . CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59:102975. PMC: 7452675. DOI: 10.1016/j.ebiom.2020.102975. View

Malik-Chaudhry H, Prabhakar K, Ugamraj H, Boudreau A, Buelow B, Dang K . TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. MAbs. 2021; 13(1):1890411. PMC: 8023237. DOI: 10.1080/19420862.2021.1890411. View

10.

Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A . The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012; 73(3):248-57. DOI: 10.1016/j.humimm.2011.12.015. View

11.

Thapa B, Caimi P, Ardeshna K, Solh M, Carlo-Stella C, Kahl B . CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020; 4(16):3850-3852. PMC: 7448593. DOI: 10.1182/bloodadvances.2020002587. View

12.

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

13.

Kellner C, Zhukovsky E, Potzke A, Bruggemann M, Schrauder A, Schrappe M . The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia. 2013; 27(7):1595-8. DOI: 10.1038/leu.2012.373. View

14.

Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, OConnor O . Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2020; 137(19):2634-2645. PMC: 8138546. DOI: 10.1182/blood.2020007512. View

15.

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U . Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15(12):1563-70. DOI: 10.1016/j.jcyt.2013.06.017. View

16.

Hirayama A, Gauthier J, Hay K, Voutsinas J, Wu Q, Gooley T . The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019; 133(17):1876-1887. PMC: 6484391. DOI: 10.1182/blood-2018-11-887067. View

17.

Bai R, Pettit G, Hamel E . Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990; 39(12):1941-9. DOI: 10.1016/0006-2952(90)90613-p. View

18.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

19.

Sehn L, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23(22):5027-33. DOI: 10.1200/JCO.2005.09.137. View

20.

Sommermeyer D, Hudecek M, Kosasih P, Gogishvili T, Maloney D, Turtle C . Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2015; 30(2):492-500. PMC: 4746098. DOI: 10.1038/leu.2015.247. View